Jaypirca Approved for Relapsed/Refractory Mantle Cell Lymphoma
As a noncovalent inhibitor of BTK, pirtobrutinib is able to reestablish BTK inhibition in patients previously treated with covalent BTK inhibitors.
As a noncovalent inhibitor of BTK, pirtobrutinib is able to reestablish BTK inhibition in patients previously treated with covalent BTK inhibitors.
Mantle cell lymphoma trials presented at ASH 2022 have broken new ground, shown promising results, and may change practice, according to researchers.
Adding ibrutinib to induction and maintenance after transplant improves failure-free survival in patients with mantle cell lymphoma, results of the TRIANGLE study suggest.
The combination of zandelisib and zanubrutinib produced high overall response rates in patients with relapsed/refractory follicular lymphoma or mantle cell lymphoma.
The combination of ibrutinib and tisagenlecleucel produced durable responses in patients with relapsed/refractory mantle cell lymphoma.
A real-world study provides a benchmark for survival in MCL patients for whom BTK inhibitor treatment has failed, according to researchers.
First-line bendamustine plus rituximab followed by ASCT and rituximab maintenance appears effective in mantle cell lymphoma.
Researchers sought to determine the treatment and survival trends for patients with mantle cell lymphoma.
The approval was based on data from the phase 1 ELEVATE-PLUS trials, which showed that acalabrutinib 100 mg tablets were bioequivalent to the acalabrutinib 100 mg capsules.
ASCT as first-line treatment for patients with MCL appears to be underutilized in the US community setting.